New FDA approvals are giving this stock some momentum.
Lannett Company, Inc. (LCI)
From The National Investor
Lannett Company, Inc. (LCI) is also at “Accumulate” after its recent surge, on the back of 1) additional FDA clearances for the company’s latest generic drug offerings and 2) the dismissal in federal court in Pennsylvania of a class action suit against the company and other generic drug makers.
Here again, I am looking chiefly at its recent move of some 30% or so from its Summer bottom. Further—as you see below—that has taken LCI shares to a place where they may finally break a stubborn down trend. Until that happens I am a little worried that the move could falter, even though I think there is far more value here than investors appreciate.
Also, I think LCI (and some other drug makers) might be looked at anew as good value/rotation
plays, especially if we finally see the overall market bog down and investors realize more than they presently do that they need to get out of momentum names and into ones that actually have strong earnings (imagine that!) and the like.
Chris Temple, The National Investor, www.nationalinvestor.com, 224-308-2587, October 10, 2017